Zepbound vs Mounjaro Cost: Same Drug, Different Insurance Math
Released · Last reviewed
Zepbound and Mounjaro are both tirzepatide from Eli Lilly. Mounjaro (diabetes) is often covered by insurance including Medicare; Zepbound (weight loss) faces the Medicare exclusion. Your diagnosis drives your cost.
- Zepbound and Mounjaro are the same molecule (tirzepatide) at identical doses.
- Mounjaro is approved for type 2 diabetes; Zepbound for weight management and sleep apnea.
- Medicare covers Mounjaro for diabetes but excludes Zepbound for weight loss.
- Your diagnosis, not your goal, often determines which brand insurance will pay for.
The same molecule
Zepbound and Mounjaro both contain tirzepatide, made by Eli Lilly, at the same doses. Pharmacologically they are identical. The difference is entirely regulatory: they are separate FDA approvals for separate indications, and that distinction drives coverage and cost.
Mounjaro is approved for type 2 diabetes; Zepbound for chronic weight management and, more recently, obstructive sleep apnea in adults with obesity. Same drug, two labels.
Why coverage differs
The coverage gap follows the indication. Medicare Part D covers Mounjaro for type 2 diabetes because diabetes drugs are not subject to the statutory weight-loss exclusion. Zepbound, indicated for weight loss, falls under that exclusion and is not covered by Medicare for obesity.
Commercial plans mirror this logic: many cover Mounjaro for a diabetes diagnosis while excluding Zepbound for weight loss, even though the molecule is the same. A patient with both type 2 diabetes and obesity may find Mounjaro dramatically cheaper through insurance.
| Attribute | Zepbound | Mounjaro |
|---|---|---|
| Molecule | Tirzepatide | Tirzepatide (identical) |
| Indication | Weight, sleep apnea | Type 2 diabetes |
| List price | ~$1,086 | ~$1,069 |
| Medicare | Excluded for weight loss | Covered for diabetes |
The cost in practice
List prices are similar — Mounjaro around $1,069 and Zepbound around $1,086 per month. But list price is rarely what patients pay. With diabetes coverage, Mounjaro can cost a modest copay. Without weight-loss coverage, Zepbound may cost full self-pay unless you use LillyDirect, which offers Zepbound vials from about $299 per month.
The practical consequence is that the same molecule can cost $25 or $1,086 depending solely on your diagnosis and which brand your prescriber codes.
| Situation | Likely best option |
|---|---|
| Type 2 diabetes | Mounjaro (often covered) |
| Obesity, no diabetes | Zepbound or compounded |
| Cash-pay, cost-first | Compounded tirzepatide |
Where compounded fits
Compounded tirzepatide is a separate, non-FDA-approved category priced at $199 to $297 per month — far below either brand’s list. It carries none of the SURMOUNT or SURPASS trial evidence and is legally restricted after the 2025 shortage resolution.
For a cash-pay patient without diabetes coverage, compounded tirzepatide is often the cheapest route, while brand Mounjaro through diabetes coverage is cheapest for those who qualify. The right answer depends on your insurance and diagnosis.
Frequently asked questions
Are Zepbound and Mounjaro the same drug?
Yes, both are tirzepatide from Eli Lilly at identical doses. They differ only in FDA-approved indication and therefore in insurance coverage.
Why is Mounjaro often cheaper for me?
If you have type 2 diabetes, Mounjaro is covered by Medicare and many commercial plans, while Zepbound for weight loss faces the Medicare exclusion.
Can I use Mounjaro for weight loss?
That is an off-label decision for your prescriber. Coverage is tied to the diabetes indication; using it off-label may affect what insurance pays.
Sources
- FDA — human drug compounding and GLP-1 status.
- Manufacturer and CMS coverage information, captured September 2026.
- Evidence ledger: evidence-ledger.csv.
The numbers behind this page
What we do not claim in this entry
Every price quoted in this entry comes from the programme's own pricing page and carries the date it was captured.
We do not claim these prices will hold. Compounded pricing moves within weeks, and a figure without a capture date is not a fact. We do not claim a compounded preparation is equivalent to an approved product: it is not FDA-approved, is not therapeutically equivalent to any brand-name product, and FDA does not review it for safety, effectiveness or manufacturing quality before marketing.
And we do not claim to be a clinical resource. Which molecule suits you, at what dose, and whether treatment is appropriate at all are questions for a prescribing clinician who has your history. This is price research, and it is only useful once those questions are settled.
Reading the price against the market
What the plan term is worth
The figures in this entry sit inside a market with a measurable shape, and that shape is what makes any single price readable.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We show month-to-month and prepaid figures side by side for that reason. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
Questions this page answers
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We compare programs on their lowest all-in monthly price and print the plan term beside every figure, so a rate that needs a commitment is labelled as one.
Where do these prices come from?
Each is read from the program's own pricing page and carries its read date. The October 15, 2026 file at /api/prices.json holds 106 records, 49 of them verified standard-dose prices, with molecule, dose class and evidence status on every record.
Which tracked programs charge less than NexLife?
Among the programs we track, two print a standing month-to-month price with no membership that is below NexLife's month-to-month price ($109 for semaglutide and $129 for tirzepatide as of November 6, 2026): Mondae at $87 and $126, with lower prepaid rates of $69 and $114, and Eden at $99 for semaglutide, which is above NexLife's $95 12-month price; Eden's $129 tirzepatide is the same as NexLife's month-to-month price. Competitor prices were read on October 15, 2026. Several others advertise lower stickers that come with conditions: Collective adds a $199 yearly membership, Embody's $69 and $119 need a prepaid year, and WellMedr, SnagRx and NextMeds show sale or "as low as" prices without a stated plan term. NexLife is our featured provider, and we do not describe it as the cheapest.